Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 5/20 | 0.50 |
| ▸ | CTSL | P07711 | 5/20 | 0.50 |
| ▸ | BRD4 | O60885 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2681682 | 0.88 | PDE4B (0.49) | CTSVCTSLBRD4 | |
| SCHEMBL2684142 | 0.82 | NPC1 (0.55) | CTSVCTSLBRD4ALDH1A1NPC1 | |
| SCHEMBL11922624 | 0.81 | ALDH1A1 (0.47) | CTSVCTSLBRD4MEN1ALDH1A1 | |
| SCHEMBL25298462 | 0.75 | FOLH1 (0.55) | CTSVCTSLBRD4MEN1ALDH1A1 | |
| SCHEMBL15968165 | 0.75 | FOLH1 (0.55) | CTSVCTSLBRD4ALDH1A1NPC1 | |
| SCHEMBL16585652 | 0.75 | FOLH1 (0.58) | CTSVCTSLMEN1ALDH1A1KMT2A | |
| SCHEMBL30442197 | 0.75 | FOLH1 (0.55) | CTSVCTSLBRD4MEN1ALDH1A1 | |
| SCHEMBL582711 | 0.74 | FOLH1 (0.51) | CTSVCTSLBRD4ALDH1A1NPC1 | |
| SCHEMBL1446554 | 0.74 | KAT2B (0.44) | BRD4FOLH1MCL1 | |
| SCHEMBL4511114 | 0.72 | ROCK2 (0.56) | CTSVCTSLMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722659-B2 | Quinazolinedione derivatives, preparation thereof and various therapeutic uses thereof | SANOFI (FR) | 2014-05-13 | — | — | US | disclosed |
| US-8722659-B2 | Quinazolinedione derivatives, preparation thereof and various therapeutic uses thereof | SANOFI (FR) | 2014-05-13 | — | — | US | disclosed |
| US-8722659-B2 | Quinazolinedione derivatives, preparation thereof and various therapeutic uses thereof | SANOFI (FR) | 2014-05-13 | — | — | US | disclosed |
| US-20120115846-A1 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND VARIOUS THERAPEUTIC USES THEREOF. | SANOFI (FR) | 2012-05-10 | — | — | US | disclosed |
| US-20120115846-A1 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND VARIOUS THERAPEUTIC USES THEREOF. | SANOFI (FR) | 2012-05-10 | — | — | US | disclosed |
| US-20120115846-A1 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND VARIOUS THERAPEUTIC USES THEREOF. | SANOFI (FR) | 2012-05-10 | — | — | US | disclosed |
| EP-2417130-A2 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND VARIOUS THERAPEUTIC USES THEREOF | SANOFI (FR) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010116088-A2 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND VARIOUS THERAPEUTIC USES THEREOF | SANOFI-AVENTIS (FR) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010116088-A2 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND VARIOUS THERAPEUTIC USES THEREOF | SANOFI-AVENTIS (FR) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115846-A1 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND VARIOUS THERAPEUTIC USES THEREOF. | CYP27B1, NDUFB3, MT-ND5 | CTSV 3300/4885CTSL 2628/4885BRD4 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.